AU2011306816A1 - Anti-ephrin-B2 antibody and use thereof - Google Patents

Anti-ephrin-B2 antibody and use thereof Download PDF

Info

Publication number
AU2011306816A1
AU2011306816A1 AU2011306816A AU2011306816A AU2011306816A1 AU 2011306816 A1 AU2011306816 A1 AU 2011306816A1 AU 2011306816 A AU2011306816 A AU 2011306816A AU 2011306816 A AU2011306816 A AU 2011306816A AU 2011306816 A1 AU2011306816 A1 AU 2011306816A1
Authority
AU
Australia
Prior art keywords
polypeptide
antibody
ephrin
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2011306816A
Other languages
English (en)
Inventor
Maria Angeles Abengozar Infantes
Jorge Luis Martinez Torrecuadrada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spanish National Cancer Research Centre
Original Assignee
Fundacion Centro Nac De Investigaciones Oncologicas Cnio
Spanish National Cancer Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Centro Nac De Investigaciones Oncologicas Cnio, Spanish National Cancer Research Centre filed Critical Fundacion Centro Nac De Investigaciones Oncologicas Cnio
Publication of AU2011306816A1 publication Critical patent/AU2011306816A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011306816A 2010-09-21 2011-09-20 Anti-ephrin-B2 antibody and use thereof Withdrawn AU2011306816A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201031402 2010-09-21
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.
PCT/ES2011/070655 WO2012038573A1 (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso

Publications (1)

Publication Number Publication Date
AU2011306816A1 true AU2011306816A1 (en) 2013-04-04

Family

ID=45873482

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011306816A Withdrawn AU2011306816A1 (en) 2010-09-21 2011-09-20 Anti-ephrin-B2 antibody and use thereof

Country Status (12)

Country Link
US (1) US9062109B2 (enExample)
EP (1) EP2620449A4 (enExample)
JP (1) JP2013542720A (enExample)
KR (1) KR20140014062A (enExample)
CN (1) CN103237812A (enExample)
AU (1) AU2011306816A1 (enExample)
BR (1) BR112013005977A2 (enExample)
CA (1) CA2812727A1 (enExample)
ES (1) ES2378976B1 (enExample)
MX (1) MX2013003168A (enExample)
RU (1) RU2013118454A (enExample)
WO (1) WO2012038573A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477B (zh) * 2015-03-03 2018-04-17 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体
US20220213214A1 (en) * 2019-05-14 2022-07-07 Sanford Health Anti-human ephrin B1 antibodies and uses thereof
WO2020242910A1 (en) * 2019-05-24 2020-12-03 The Regents Of The University Ofcalifornia Compositions and methods for treating cancer
TW202547871A (zh) * 2024-03-27 2025-12-16 美商麥第爾醫療公司 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法
CN121159668A (zh) * 2025-09-12 2025-12-19 北京威斯克生物医药有限公司 Ephrin-B2重组蛋白及其疫苗、制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
EP1954720A1 (en) * 2005-10-31 2008-08-13 The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health Antibodies and immunotoxins that target human glycoprotein nmb
RU2451031C2 (ru) * 2006-01-20 2012-05-20 Дженентек, Инк. Антитела к эфрину в2 и способы их применения
PL1972637T3 (pl) * 2007-03-19 2012-01-31 Univ Stuttgart Antagoniści selektywni wobec huTNFR1
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Also Published As

Publication number Publication date
CN103237812A (zh) 2013-08-07
WO2012038573A1 (es) 2012-03-29
CA2812727A1 (en) 2012-03-29
KR20140014062A (ko) 2014-02-05
MX2013003168A (es) 2013-08-21
US9062109B2 (en) 2015-06-23
US20130287795A1 (en) 2013-10-31
EP2620449A1 (en) 2013-07-31
ES2378976B1 (es) 2013-05-06
RU2013118454A (ru) 2014-10-27
EP2620449A4 (en) 2014-03-26
JP2013542720A (ja) 2013-11-28
BR112013005977A2 (pt) 2019-09-24
ES2378976A1 (es) 2012-04-19

Similar Documents

Publication Publication Date Title
US20240343824A1 (en) Binding molecules that inhibit cancer growth
JP7607498B2 (ja) 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP5719596B2 (ja) 抗体及びその誘導体
EP2835380A1 (en) Method of blocking vascular leakage using an anti-Ang2 antibody
US9062109B2 (en) Anti-ephrin-B2 antibody and compositions comprising it
CN107098970A (zh) 结合细胞内prl‑1多肽或prl‑3多肽的抗体
RS66856B1 (sr) Antitela koja se vezuju za sortilin i inhibiraju vezivanje progranulina
KR102887692B1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
JP2018513141A (ja) ヒトカドヘリン−１７、ヒトカドヘリン−５、ヒトカドヘリン−６およびヒトカドヘリン−２０のｒｇｄモチーフに特異的に結合する薬剤
JP7673981B2 (ja) 抗ｃｘｃｒ２抗体およびその使用
CN107614524A (zh) 治疗
AU2021209740A1 (en) SEMG2 antibody and use thereof
WO2021083248A1 (zh) 抗tspan8单克隆抗体及其用途
CN120025456B (zh) 一种抗vegfa融合构建体及其制备方法和应用
US11945858B2 (en) Antibodies and antibody fragments against HNAV1.7 channel and their use in pain and cancer indications
KR20250123919A (ko) 항-tgf베타 수용체 1 항체 및 그의 용도

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 19 AUG 2015 .